Prospective analysis of parametric response map-derived MRI biomarkers: Identification of early and distinct glioma response patterns not predicted by standard radiographic assessment

Clinical Cancer Research

Volumn 17, Issue 14, 2011, Pages 4751-4760

  Galbán, Craig J ^a   Chenevert, Thomas L ^a   Meyer, Charles R ^a   Tsien, Christina ^a   Lawrence, Theodore S ^a   Hamstra, Daniel A ^a   Junck, Larry ^a   Sundgren, Pia C ^a   Johnson, Timothy D ^a   Galbán, Stefanie ^a   Sebolt Leopold, Judith S ^a   Rehemtulla, Alnawaz ^a   Ross, Brian D ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; GADOLINIUM PENTETATE; TEMOZOLOMIDE;

ADULT; APPARENT DIFFUSION COEFFICIENT; ARTICLE; BRAIN BLOOD VOLUME; BRAIN RADIOGRAPHY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GLIOMA; HUMAN; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAMETRIC RESPONSE MAP; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RADIOLOGICAL PARAMETERS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BRAIN NEOPLASMS; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 79960411354     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2098     Document Type: Article

References (41)

1. Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66.
2. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80. (Pubitemid 20195640)
3. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
4. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
5. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:2712-8.
6. Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 2010;11:92-102.
7. Chenevert TL, Ross BD. Diffusion imaging for therapy response assessment of brain tumor. Neuroimaging Clin 2009;19:559-71.
8. Lacerda S, Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin 2009;19:527-57.
9. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36. (Pubitemid 32045900)
10. Hamstra DA, Lee KC, Moffat BA, Chenevert TL, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol 2008;1:187-94.
11. Liimatainen T, Hakumaki JM, Kauppinen RA, Ala-Korpela M. Monitoring of gliomas in vivo by diffusion MRI and (1)H MRS during gene therapy-induced apoptosis: interrelationships between water diffusion and mobile lipids. NMR Biomed 2009;22:272-9.
12. Liu Y, Bai R, Sun H, Liu H, Zhao X, Li Y. Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. Clin Radiol 2009;64:1067-74.
13. Brix G, Kiessling F, Lucht R, Darai S, Wasser K, Delorme S, et al. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn Reson Med 2004;52:420-9. (Pubitemid 39025290)
14. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: experimental comparison and preliminary results. Magn Reson Med 1996;36:726-36.
15. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-25.
16. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249-65. (Pubitemid 20248610)
17. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997;7:91-101. (Pubitemid 28365643)
18. Degani H, Gusis V, Weinstein D, Fields S, Strano S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 1997;3:780-2. (Pubitemid 27298724)
19. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552-8.
20. Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006;58:1099-107; discussion 1099-107. (Pubitemid 43879544)
21. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-98. (Pubitemid 37444849)
22. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524-9. (Pubitemid 40530291)
23. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 2010;31:538-48.
24. Hiramatsu R, Kawabata S, Miyatake SI, Yamada Y, Kuroiwa T. New imaging assessment of glioblastoma patients treated by boron neutron capture therapy: functional diffusion map. Proceedings of the 14th International Congress on Neutron Capture Therapy; 2010 Oct 25-29; Buenos Aires, Argentina.
25. Lin YC, Wang CC, Wai YY, Wan YL, Ng SH, Chen YL, et al. Significant temporal evolution of diffusion anisotropy for evaluating early response to radiosurgery in patients with vestibular schwannoma: findings from functional diffusion maps. AJNR Am J Neuroradiol 2010;31:269-74.
26. Ellingson BM, Rand SD, Malkin MG, Schmainda KM. Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. J Neurooncol 2010;97:419-23.
27. Galban CJ, Mukherji SK, Chenevert TL, Meyer CR, Hamstra DA, Bland PH, et al. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol 2009;2:184-90.
28. Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA, et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 2007;9:1003-11. (Pubitemid 350255347)
29. Ma B, Meyer CR, Pickles MD, Chenevert TL, Bland PH, Galban CJ, et al. Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging 2009;21:276-87.
30. Galban CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 2009;15:572-6.
31. Tsien C, Galban CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 2010;28:2293-9.
32. Hamstra DA, Galban CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien C, et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008;26:3387-94.
33. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20:1635-42. (Pubitemid 34260545)
34. Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 1977;47:329-35. (Pubitemid 8170121)
35. Cao Y, Tsien CI, Nagesh V, Junck L, Ten Haken R, Ross BD, et al. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006;64:876-85. (Pubitemid 43183588)
36. Meyer CR, Boes JL, Kim B, Bland PH, Zasadny KR, Kison PV, et al. Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1997;1:195-206.
37. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10. (Pubitemid 23133591)
38. Sulman EP, Guerrero M, Aldape K. Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol 2009;19:142-9.
39. Potti A, Schilsky RL, Nevins JR. Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med 2010;2:28cm13.
40. Schilsky RL. How not to treat cancer. Lancet Oncol 2008;9:504-5. (Pubitemid 351722575)
41. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010;9:363-6.